Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab

PURPOSE: Cetuximab and panitumumab are monoclonal antibodies that target the epidermal growth factor receptor (EGFR) and are approved for the treatment of patients with KRAS wild-type meta-static colorectal cancer. There are no data that describe the activity of panitumumab in patients with progress...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Wadlow, Raymond C., Hezel, Aram F., Abrams, Thomas A., Blaszkowsky, Lawrence S., Fuchs, Charles S., Kulke, Matthew H., Kwak, Eunice L., Meyerhardt, Jeffrey A., Ryan, David P., Szymonifka, Jackie, Wolpin, Brian M., Zhu, Andrew X., Clark, Jeffrey W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2012
Konular:
Clinical Trial Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3267814/
https://ncbi.nlm.nih.gov/pubmed/22210091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0452
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller